News GSK takes fight to AZ/Merck & Co with first-line ovarian can... The FDA has approved GlaxoSmithKline’s Zejula as first-line maintenance treatment for women with platinum-responsive ovarian cancer, competing against AstraZeneca and Merck & Co’s class
Events Partner Content PARP & DNA Damage Response Inhibitors Summit 2020 PARP DNA Damage Response Summit DDR Synthetic Lethality
News ESMO 2019 – new data could unlock bigger market for PARP inh... AstraZeneca and GlaxoSmithKline could both benefit from new data that should widen the market for PARP inhibitors as first-l
News Mixed data from lung cancer trials on show at WCLC Highlights of the WCLC show include new data for AstraZeneca's Tagrisso, Summit's ivonescimab, MSD/Daiichi's I-DXd, and BMS/Systimmune's iza-bren.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
